Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Brian L SamuelsSant P ChawlaNeeta SomaiahArthur P StaddonKeith M SkubitzMohammed M MilhemPamela E KaiserDavid C PortnoyDennis A PriebatMark S WalkerEdward J StepanskiPublished in: Cancer (2017)
The current study provides evidence of potential activity of pazopanib in the liposarcoma subset of patients with soft tissue sarcoma that was specifically excluded from the phase 3 PALETTE trial of other soft tissue sarcoma types. Cancer 2017;123:4640-4647. © 2017 American Cancer Society.